Core Viewpoint - Agilon Health, Inc. is facing a securities fraud lawsuit initiated by the Rosen Law Firm, with a lead plaintiff deadline set for March 2, 2026, for investors who purchased securities between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that Agilon's management made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [1] - It is claimed that Agilon overstated the positive financial impact from strategic actions taken to mitigate risks, leading to materially false representations about the company's business and prospects [1] - Investors are encouraged to join the class action without incurring out-of-pocket fees, as the Rosen Law Firm operates on a contingency fee basis [1] Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [1] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [1] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in handling such cases [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased agilon securities between February 26, 2025, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding agilon's financial guidance for 2025, which they knew was unattainable due to industry challenges [5]. - It is claimed that defendants overstated the positive financial impact of strategic actions taken by agilon, leading to materially false statements about the company's business and prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result of these misleading statements [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - The Class Period for the agilon securities is from February 26, 2025, to August 4, 2025 [1] - Investors who purchased agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3] Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding agilon's financial guidance for 2025, which they knew was unattainable due to industry challenges [5] - It is claimed that defendants overstated the positive financial impact of strategic actions taken by agilon to mitigate risks, leading to materially false statements about the company's business and prospects [5] - The lawsuit asserts that when the true information became public, investors suffered damages [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by March 2, 2026 [2][4]. Group 1: Allegations Against Agilon Health - The complaint alleges that agilon health and its executives made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [4]. - It is claimed that the company overstated the financial benefits from strategic actions taken to mitigate risks, leading to materially false representations about its business and prospects [4]. - Following the release of disappointing second-quarter results on August 4, 2025, agilon health's stock plummeted by 51.5% on August 5, 2025, after the company suspended its full-year 2025 financial guidance [5]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased agilon health securities between February 26, 2025, and August 4, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is also typical of the class members, with the option for any class member to move the court for this role [6]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding agilon health's conduct [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - The Class Period for the agilon securities is from February 26, 2025, to August 4, 2025 [1]. - Investors who purchased agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 2, 2026 [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding agilon's business and financial guidance for 2025, which they knew or should have known was unattainable due to industry challenges [5]. - It is claimed that the defendants overstated the positive financial impact from strategic actions taken by agilon to mitigate risks, leading to materially false statements about the company's operations and prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4].

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in agilon health, inc. ("agilon health, inc." or the "Company") (NYSE: AGL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of agilon health, inc. investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/ag ...

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against agilon health, inc. (NYSE: AGL) for allegedly issuing misleading statements and failing to disclose critical information during the class period from February 26, 2025, to August 4, 2025 [1]. Allegations - The lawsuit claims that the defendants provided guidance for 2025 that they knew or should have known was unrealistic due to significant industry challenges [1]. - It is alleged that the defendants overstated the immediate financial benefits from strategic actions taken by agilon to mitigate risks [1]. - Consequently, the statements made by the defendants regarding agilon's business, operations, and future prospects were materially false and misleading [1]. Class Action Details - The deadline for shareholders to register for the class action is March 2, 2026 [1]. - Shareholders who purchased AGL shares during the specified class period are encouraged to register for potential lead plaintiff appointment, although it is not necessary to participate in any recovery [1]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. (AGL) for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by March 2, 2026 [1] Summary by Relevant Sections Legal Action - A federal securities class action has been filed against agilon health, alleging that the company and its executives made false and misleading statements regarding their financial guidance and business operations [1] - The complaint claims that the defendants issued guidance for 2025 that they knew or should have known was unattainable due to industry headwinds [1] - The lawsuit also alleges that the defendants overstated the financial impact of strategic actions taken to reduce risk, leading to materially false statements about the company's prospects [1] Financial Impact - On August 4, 2025, agilon health reported its second-quarter results, indicating that industry challenges were more severe than previously anticipated, and subsequently suspended its full-year 2025 financial guidance [1] - Following this announcement, agilon health's stock price dropped by 51.5% on August 5, 2025, reflecting the market's reaction to the revised outlook [1] Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the group [1] - Any member of the class can apply to serve as lead plaintiff or choose to remain an absent class member, with their ability to recover not affected by this decision [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][4]. Group 1: Legal Investigation and Claims - The law firm is looking into claims against agilon health for misleading statements and failure to disclose critical information regarding the company's financial guidance and operational challenges [4]. - Investors who purchased agilon health securities between February 26, 2025, and August 4, 2025, are reminded of the March 2, 2026, deadline to seek the role of lead plaintiff in a federal securities class action [2][6]. Group 2: Company Performance and Stock Impact - On August 4, 2025, agilon health announced the suspension of its full-year 2025 financial guidance, leading to a significant stock price drop of 51.5% on August 5, 2025 [5]. - The company's Executive Chair acknowledged that industry headwinds were more severe than previously anticipated, indicating challenges in achieving the previously issued financial guidance [5]. Group 3: Firm Background and Recovery - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995, with offices across multiple states [3]. - The firm encourages anyone with information regarding agilon health's conduct to come forward, including whistleblowers and former employees [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to allegations of violations of federal securities laws, specifically regarding misleading statements and guidance issued by the company [2][4]. Group 1: Legal Investigation - The law firm is encouraging agilon health investors who suffered losses exceeding $50,000 between February 26, 2025, and August 4, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against agilon health, with a deadline of March 2, 2026, for investors to seek the role of lead plaintiff [2][5]. - The complaint alleges that agilon health and its executives made false and misleading statements regarding the company's financial guidance and the impact of strategic actions taken to reduce risk [4]. Group 2: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. - The firm is actively seeking information from whistleblowers, former employees, and shareholders regarding agilon health's conduct [6].